儿童癌症幸存者的下丘脑-垂体疾病:患病率、危险因素与长期健康结局
该回顾性队列纳入3141例儿童癌症幸存者(中位年龄31.7岁,中位随访24.1年),分析下丘脑-垂体(HP)疾病患病率、危险因素及不良健康结局。接受HP放疗者(n=1089)中生长激素缺乏(GHD)患病率为40.2%,无HP放疗者GHD为6.2%。HP放疗、中枢神经系统损伤及化疗与HP疾病相关,HP疾病与身材矮小、骨密度严重不足、肥胖等不良结局独立相关。
要点
- HP放疗(GHD等任何剂量,ACTHD>30 Gy)、烷化剂、鞘内化疗等为HP疾病危险因素。
- HP疾病与身材矮小、骨密度严重不足、肥胖、衰弱及认知功能受损等不良结局相关。
核心结论
- HP放疗、中枢神经系统损伤及程度较轻的化疗与HP疾病相关,HP疾病又与多种不良健康结局相关。
研究设计与样本
- 回顾性队列研究,并采用横断面健康结局分析;共纳入3141例儿童癌症幸存者,中位年龄31.7岁,中位随访24.1年。
主要发现
- 接受HP放疗者(n=1089)中,GHD患病率40.2%、TSHD 11.1%、LH/FSHD 10.6%、ACTHD 3.2%、CPP 0.9%;无HP放疗者GHD为6.2%,其他HP疾病均<1%。
- 与HP疾病独立相关的临床因素包括HP放疗(GHD、TSHD、LH/FSHD为任何剂量,ACTHD为>30 Gy)、烷化剂(GHD、LH/FSHD)、鞘内化疗(GHD)、伴分流术的脑积水(GHD、LH/FSHD)、癫痫发作(TSHD、ACTHD)及卒中(GHD、TSHD、LH/FSHD、ACTHD)。
- 与HP疾病独立相关的不良结局包括身材矮小(GHD、TSHD)、骨密度严重不足(GHD、LH/FSHD)、肥胖(LH/FSHD)、衰弱(GHD)、躯体健康相关生活质量受损(TSHD)、性功能障碍(LH/FSHD)、记忆与加工速度受损(GHD、TSHD)。
临床怎么用
- 对接受HP放疗、中枢神经系统损伤或相关化疗的儿童癌症幸存者应长期监测HP功能,并关注身材矮小、骨密度、肥胖、衰弱、性功能及认知等结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Data on hypothalamic-pituitary (HP) disorders in systematically evaluated childhood cancer survivors are limited. OBJECTIVE: To describe prevalence, risk factors, and associated adverse health outcomes of deficiencies in GH deficiency (GHD), TSH deficiency (TSHD), LH/FSH deficiency (LH/FSHD), and ACTH deficiency (ACTHD), and central precocious puberty (CPP). DESIGN: Retrospective with cross-sectional health outcomes analysis. SETTING: Established cohort; tertiary care center. PATIENTS: Participants (N = 3141; median age, 31.7 years) were followed for a median 24.1 years. MAIN OUTCOME MEASURE: Multivariable logistic regression was used to calculate ORs and 95% CIs for associations among HP disorders, tumor- and treatment-related risk factors, and health outcomes. RESULTS: The estimated prevalence was 40.2% for GHD, 11.1% for TSHD, 10.6% for LH/FSHD, 3.2% for ACTHD, and 0.9% for CPP among participants treated with HP radiotherapy (n = 1089), and 6.2% for GHD, and <1% for other HP disorders without HP radiotherapy. Clinical factors independently associated with HP disorders included HP radiotherapy (at any dose for GHD, TSHD, LH/FSHD, >30 Gy for ACTHD), alkylating agents (GHD, LH/FSHD), intrathecal chemotherapy (GHD), hydrocephalus with shunt placement (GHD, LH/FSHD), seizures (TSHD, ACTHD), and stroke (GHD, TSHD, LH/FSHD, ACTHD). Adverse health outcomes independently associated with HP disorders included short stature (GHD, TSHD), severe bone mineral density deficit (GHD, LH/FSHD), obesity (LH/FSHD), frailty (GHD), impaired physical health-related quality of life (TSHD), sexual dysfunction (LH/FSHD), impaired memory, and processing speed (GHD, TSHD). CONCLUSION: HP radiotherapy, central nervous system injury, and, to a lesser extent, chemotherapy are associated with HP disorders, which are associated with adverse health outcomes.
引用
- van Iersel L, Li Z, Srivastava DK, et al. Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes. J Clin Endocrinol Metab. 2019. PMID: 31373627. doi:10.1210/jc.2019-00834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。